ClinicalTrials.gg
CompletedNCT07769450Updated Aug 18, 2026

Stone Cone Device vs. Standard URS for Proximal Ureteral Calculi

An interventional study of Ureteroscopic Pneumatic Lithotripsy with Cone Device and Standard Ureteroscopic Pneumatic Lithotripsy in Ureter Calculi, sponsored by Provincial Headquarter Teaching Hospital Gilgit. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Provincial Headquarter Teaching Hospital Gilgit · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled Oct 2022, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Retrograde migration of stone fragments into the kidney during ureteroscopic lithotripsy (URS) for proximal ureteral stones is a common technical challenge, occurring in 5-40% of cases. This can lead to residual fragments and lower stone-free rates. The Stone Cone is an anti-retropulsion device designed to trap fragments and prevent their migration. This study will test the hypothesis that the use of the Stone Cone during URS pneumatic lithotripsy will result in a significantly higher stone clearance rate at 48 hours post-procedure compared to the standard technique without the device.

02

Conditions studied

  • Ureter Calculi

Browse trials for

Keywords

  • Ureteroscopy
  • Stone Cone Device
  • Pneumatic Lithotripsy
  • Stone Clearance
  • Randomized Controlled Trial
03

In context

Calculi

51 studies on the registry are indexed under Calculi; 6 are open to participants now.

This study's enrollment of 100 is above the median of 74 across 43 interventional studies indexed under Calculi.

Browse Calculi studies →

Lead sponsor

Provincial Headquarter Teaching Hospital Gilgit is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A solitary proximal ureteral stone ≤ 2 cm in size as confirmed by imaging.
  • Normal renal function.

Exclusion criteria

Exclusion Criteria:

  • Active urinary tract infection (clinical features or pyuria).
  • Bleeding disorder (abnormal or activated partial thromboplastin time).
  • Chronic kidney disease (raised urea and creatinine).
  • Stone > 2 cm in size.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Group A: Stone Cone Device

    Participants will undergo ureteroscopic pneumatic lithotripsy for a proximal ureteral calculus. The Stone Cone device will be positioned fluoroscopically proximal to the stone before fragmentation and used to prevent retrograde stone migration and trap fragments for extraction.

    Procedure: Ureteroscopic Pneumatic Lithotripsy with Cone Device

  • Active comparator
    Group B: Standard URS

    Participants will undergo standard ureteroscopic pneumatic lithotripsy for a proximal ureteral calculus without the use of any anti-retropulsion device.

    Procedure: Standard Ureteroscopic Pneumatic Lithotripsy

Interventions

  • ProcedureUreteroscopic Pneumatic Lithotripsy with Cone Device

    Patients will undergo ureteroscopic pneumatic lithotripsy under general anesthesia. The Stone Cone device (Boston Scientific, Natick, MA) will be advanced through the ureteroscope and positioned fluoroscopically proximal to the calculus before fragmentation. The device will create a mechanical barrier to prevent retrograde stone migration into the renal pelvis and will be used to trap and extract fragments upon withdrawal. A ureteral double-J stent will be placed at the end of the procedure.

  • ProcedureStandard Ureteroscopic Pneumatic Lithotripsy

    Patients will undergo standard ureteroscopic pneumatic lithotripsy under general anesthesia without the use of any anti-retropulsion device. Stone fragmentation and fragment extraction will be performed using standard tools (pneumatic lithotripter, grasping forceps, or basket) as per the surgeon's discretion. A ureteral double-J stent will be placed at the end of the procedure.

06

What researchers measure

Primary outcomes

  1. Stone Clearance Rate

    The proportion of participants achieving a stone-free status, defined as the absence of stones on plain X-ray of the kidneys, ureters, and bladder (KUB) and abdominal ultrasonography performed 48 hours after the ureteroscopic lithotripsy procedure.

    Time frame: 48 hours

Secondary outcomes

  1. Incidence of Intraoperative Complications

    The number of participants experiencing complications such as ureteral perforation or significant bleeding during the procedure.

    Time frame: 2 hours

  2. Operative Time

    The total duration of the ureteroscopic procedure, measured in minutes.

    Time frame: 120 minutes

  3. Hospital Stay Duration

    The length of the patient's hospital stay following the procedure.

    Time frame: 5 days

07

Study locations

1 site
  • Provincial Headquarter Teaching Hospital, Gilgit.
    Gilgit, Gilgit-Baltistan 54000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers due to institutional policies regarding patient confidentiality and data protection. Additionally, the trial is a single-center study with a modest sample size, and the research team does not have an established infrastructure for data-sharing or the necessary resources to support external data requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2026, 42 months.

Of 16 interventional studies with no phase under Calculi, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 60. This study's 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 18, 2026
StartActual
Oct 1, 2022
Primary completionActual
Apr 30, 2026
CompletionActual
Jun 30, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769450
Lead sponsor
Provincial Headquarter Teaching Hospital Gilgit
Responsible party
Akbar Shah (Principal Investigator, Provincial Headquarter Teaching Hospital Gilgit) — Principal investigator
First posted
Aug 18, 2026
Start date
Oct 1, 2022
Primary completion
Apr 30, 2026
Completion
Jun 30, 2026
Last update
Aug 18, 2026

Study contacts

Khawar Suliman, MBBS, FCPS
study director · Provincial Headquarter Teaching Hospital Gilgit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion